• S1PR3 Drives Neuronal Apoptosis After ICH

  2026-09-24

  A mouse intracerebral hemorrhage model and HT22 cell experiments identify S1PR3 as a contributor to neuronal apoptosis, linking S1P stimulation with CCL2, TNF-α, PI3K/AKT signaling, and cleaved caspase-3. Pharmacological S1PR3 inhibition reduced apoptosis-associated readouts and improved neurobehavioral outcomes in the study, supporting further investigation of this receptor pathway while leaving important questions about causality and clinical translation open.

• 3-Deazaadenosine: Mechanism, Evidence & Use

  2026-09-24

  3-Deazaadenosine is a S-adenosylhomocysteine hydrolase inhibitor that can alter cellular methylation by increasing intracellular SAH and changing the SAH-to-SAM ratio. Product information also reports preclinical antiviral activity against Ebola and Marburg viruses, but these findings do not establish clinical efficacy or direct effects on m6A pathways.

• 3-Deazaadenosine: Global vs Targeted Methylation

  2026-09-23

  3-Deazaadenosine is an S-adenosylhomocysteine hydrolase inhibitor that can perturb methylation broadly, but it is not a selective probe of METTL14 or RNA m6A. This article uses a recent ulcerative colitis study to show how to distinguish metabolic methylation effects from transcript-specific regulation when designing and interpreting experiments.

• Dovitinib (TKI-258): RTK Signaling Research

  2026-09-23

  Dovitinib, also called TKI-258 and CHIR-258, is a multitargeted receptor tyrosine kinase inhibitor used to study FLT3, c-Kit, FGFR, VEGFR, and PDGFR signaling. Its reported low-nanomolar activity and downstream effects make it a useful research tool for apoptosis induction in cancer cells, but assay conditions and model context must guide interpretation.

• ATRX Deficiency Sensitizes Glioma to RTK Inhibitors

  2026-09-22

  The reference study identifies ATRX deficiency as a potential determinant of sensitivity to multi-targeted receptor tyrosine kinase and PDGFR inhibitors in high-grade glioma cells. Its combination data with temozolomide support ATRX-aware pharmacology and clinical-trial stratification, while remaining preliminary because the evidence is primarily cellular.

• tRF16–ALKBH5–NFKBIA Axis in Osteoarthritis

  2026-09-22

  This study identifies tRF16 as an overexpressed small RNA that worsens osteoarthritis through an ALKBH5–NFKBIA–NF-κB regulatory axis. By combining patient cartilage, an OA rat model, and IL-1β-treated chondrocytes, the work connects tRF-mediated epitranscriptomic regulation with inflammatory cartilage damage and proposes a mechanistically testable biomarker pathway.

• Romidepsin (FK228): Mechanism-to-Assay Research Guide

  2026-09-21

  Explore how Romidepsin (FK228) links selective HDAC1/2 inhibition with chromatin, apoptosis, and cell-cycle phenotypes. This guide also translates multidimensional proteomics into a practical framework for validating target engagement rather than relying on viability data alone.

• TOP1, cGAS, and PD-L1 in Cervical Cancer

  2026-09-21

  The reference study identifies a mechanistic link between HPV oncoproteins, TOP1-associated DNA damage responses, cGAS activation, and PD-L1 expression in cervical cancer. Its findings position the TOP1–cGAS–PD-L1 axis as a useful framework for studying how viral oncogenesis connects genomic stress with tumor-promoting inflammation and immune evasion.

• Dual-Pathway Nanotherapy for Gefitinib Resistance

  2026-09-20

  Deng and colleagues developed a rational combination strategy that pairs gefitinib with crizotinib to suppress PI3K–AKT signaling and compensatory ERK activation in gefitinib-resistant lung adenocarcinoma. Integrated transcriptomics, phospho-proteomics, cell models, xenografts, zebrafish metastasis assays, and a dual-drug nanoparticle platform provide a multiscale framework for addressing both resistance and metastatic progression.

• Cepharanthine in Endometriosis: Organoid and In Vivo Evidenc

  2026-09-19

  A 2026 study evaluated Cepharanthine across immortalized stromal cells, patient-derived endometriotic cells, eutopic endometrial organoids, and a murine peritoneal model. Its central finding is that this biscoclaurine alkaloid suppresses lesion growth through cell-cycle arrest, DNA damage with impaired repair, and mitochondria-associated apoptosis, while also demonstrating the value of organoids for preclinical endometriosis research.

• iRhom2 in Olfaction: OR Regulation and Adaptation

  2026-09-18

  Azzopardi and colleagues identify iRhom2 as an olfactory sensory neuron regulator linked to odorant receptor expression and activity-dependent adaptation. Their combination of knockout-mouse transcriptomics, spatial validation, and heterologous receptor activation supports an iRhom2–ADAM17 signaling model while leaving several causal and translational questions open.

• Indometacin Sodium: Assay Workflows & Optimization

  2026-09-18

  Build reproducible inflammation, proliferation, oligodendrocyte differentiation, and pathway assays with Indometacin Sodium Trihydrate. This practical guide connects concentration selection, vehicle control, mechanistic readouts, and troubleshooting to help researchers distinguish COX-dependent effects from broader cellular responses.

• Danazol Assay Workflows for Endocrine Research

  2026-09-17

  This scenario-based guide explains how Danazol supports reproducible cell viability, steroidogenesis, and endocrine-model workflows. It connects mechanistic benchmarks with practical solvent, storage, control, and vendor-selection decisions for research use of SKU C3644.

• Angiotensin Peptides Enhance SARS-CoV-2 Binding

  2026-09-17

  Oliveira et al. show that naturally occurring angiotensin peptides can increase SARS-CoV-2 spike-protein binding to host receptors, with N-terminally truncated forms producing particularly strong effects. The study provides a mechanistic link between renin–angiotensin biology and viral receptor engagement while also defining important experimental limits: the evidence comes from binding assays rather than infection or clinical studies.

• X-Gal for Reproducible Reporter Workflows

  2026-09-16

  This scenario-based guide explains how X-Gal (SKU A2539) supports β-galactosidase reporter assays, blue-white colony screening, and molecular cloning while avoiding common interpretation errors in viability and cytotoxicity experiments. It covers substrate compatibility, stock handling, data interpretation, and practical vendor-selection criteria.

8024 records 3/535 page Previous Next 12345 下5页 Last page